Medicare coverage of Alzheimer’s drug Aduhelm may soon be dramatically limited. The CMS is asking for public comments before finalizing the decision. Last week,…
It seems like, following the FDA’s controversial July 2021 approval of Biogen’s Alzheimer’s drug Aduhelm, everyone is mad at someone. Here are the main…
Aduhelm’s clinical trials shines a light on why representation is crucial in the search for effective Alzheimer’s treatments. The Food and Drug Administration’s (FDA)…
European drug regulators dealt a blow to Biogen, deciding against allowing Aduhelm onto the market. Meanwhile, the company slashed the price of its drug…
Controversial Alzheimer’s drug Aduhelm underwhelmed in early sales. Despite poor performance, some neurologists hope the drug will mean more new Alzheimer’s treatments — and…
In the lead-up to European regulators’ December decision on Aduhelm’s approval for use in the European Union, an expert panel declined to give the…
Medicare premiums are going up in price across the board thanks in part to the anticipated cost of covering Aduhelm — but that doesn’t…